First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Authors:
Open Access
- 3 June 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 533
Abstract
Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of regorafenib when administered in first-line to frail patients with advanced CRC. Frail patients without prior advanced colorectal cancer treatment were included in the study. Definition of frailty was defined per protocol based on dependency criteria, presence of chronic comorbid pathologies and/or geriatric features. Main objective: to assess progression-free survival (PFS) rate at 6 months. Treatment consisted of 28-day cycles of orally administered regorafenib 160 mg/day (3 weeks followed by 1 week rest). Forty-seven patients were included in the study. Median age was 81 years (range 63–89). Frailty criteria: dependency was observed in 26 patients (55%), comorbidities in 27 (57%) and geriatric features in 18 (38%). PFS rate at 6 months was 45% (95% confidence interval [CI] 30–60]. Median PFS was 5.6 months (95%CI 2.7–8.4). Median overall survival (OS) was 16 months (95%CI 7.8–24). Complete response, partial response and stable disease were observed in one, two and 21 patients respectively (objective response rate 6.4%; disease control rate 51%). Thirty-nine patients (83%) experienced grade 3–4 adverse events (AEs). The most common grade 3–4 AEs were hypertension (15 patients; 32%), asthenia (14; 30%), hypophosphatemia (6; 13%); diarrhea (4; 8%), hand-foot-skin reaction (4; 8%). There were two toxic deaths (4.2%) (grade 5 rectal bleeding and death not further specified). Dose reduction was required in 26 patients (55%) and dose-delays in 13 patients (28%). The study did not meet the pre-specified boundary of 55% PFS rate at 6 months. Toxicity observed (83% patients experienced grade 3 and 4 AEs) preclude its current use in clinical practice on this setting. Disease control rate and overall survival results are interesting and might warrant further investigation to identify those who benefit from this approach. This trial was prospectively registered at EudraCT ( 2013–000236-94 ). Date of trial registration: April 9th, 2013.Keywords
Funding Information
- Bayer Hispania (The Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD), Madrid, Spain)
This publication has 21 references indexed in Scilit:
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trialThe Lancet Oncology, 2013
- Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib studyAnnals of Oncology, 2013
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid TumorsClinical Cancer Research, 2012
- First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According toKRASStatus from a Spanish TTD Group StudyThe Oncologist, 2012
- Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trialThe Lancet, 2011
- First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)Critical Reviews in Oncology/Hematology, 2011
- Aging, frailty and age-related diseasesBiogerontology, 2010
- Next generation oncology drug development: opportunities and challengesNature Reviews Clinical Oncology, 2009
- Frailty Syndrome: A Transitional State in a Dynamic ProcessGerontology, 2009